Chicago, United States
SimBioSys, Inc. is a pioneering TechBio company founded in 2016 with the ambitious slogan "Redefine Precision Medicine. Revolutionize Patient Care. Defeat Cancer." The company leverages artificial intelligence and biophysical modeling to harness the power of spatial biophysics. Its primary goal is to redefine precision medicine, transform patient care, and ultimately defeat cancer.
SimBioSys aims to empower clinicians and researchers with a more informed understanding of a patient’s tumor, enabling them to assess all available options and deliver on the promise of truly individualized patient care. The company operates in the Biotechnology, Life Sciences, and Pharmaceutical industries, with its headquarters in the United States.
The most recent funding milestone for SimBioSys is a noteworthy $15.00M Series A investment on 26 October 2021. This investment was made by a consortium of leading venture capital and healthcare organizations, including AV8 Ventures, Genoa Ventures, Heritage Group, Mayo Clinic, and Northpond Ventures. For more information about SimBioSys, visit their website at https://www.simbiosys.com/.
